Photo of Bridget Dooling being interviewed by Tom Temin at a recording studio.


The GW Regulatory Studies Center scholars regularly conduct applied research to understand regulatory policy and practice from a public interest perspective. Our content often takes the form of public interest comments, formal testimony, working papers, policy insights, and short commentaries analyzing the most pressing issues in regulatory policy. View the rest of our material by the different types of publications listed on this page or our research areas.


What We Publish

Image of speech bubbles, indicating comments

Public Comments & Testimonies

Scholarly analysis of the potential effects of particular rulemakings from federal agencies, and advice to Congress on how to improve the rulemaking process.

Image of magnifying glass over speech bubble

Commentaries & Insights

Short-form publications intended for all audiences which provide easy to access analysis of regulatory policy.

Image of an open book

Books & Reports

Formal publications, often completed with other leading organizations and individuals, providing a thorough understanding of regulations and the rulemaking process.

Image of document with cogs


The weekly Regulation Digest contains everything you need to know about regulatory policy today, and our monthly Center Update gives you all of the latest from our team.


Latest Publications 

Telemedicine & Initiating Buprenorphine Treatment

February 23, 2021
Federal regulators dramatically reduced the barriers to using telemedicine to treat opioid use disorder in response to the COVID-19 public health emergency. Public health experts have long argued that health care practitioners can provide high-quality treatment for opioid use disorder via telemedicine.

Regulatory Sentiment and Uncertainty under the Trump Administration

February 10, 2021
Using newspaper text, Zhoudan Xie tracks sentiment and uncertainty about regulation and discusses how they changed during administrations.

A Last-Minute Attempt to Partially X the X Waiver

February 03, 2021
The Biden administration changed course at HHS and decided not to publish guidelines for buprenorphine prescriptions to treat opioid use disorder due to “legal and clinical concerns.”

The Regulators' New Marching Orders

January 27, 2021
While Biden's Inauguration Day actions acknowledge longstanding regulatory review practices, they also foreshadow a move away from the bipartisan emphasis on evidence-based policy and signal a much more progressive, and less humble, approach to regulating.

The Regulatory Savvy of Biden’s Early Executive Actions

January 26, 2021
Just hours after his inauguration, President Joe Biden set in motion a series of executive actions that will shape his regulatory agenda.